Three lines into an email you have already rewritten, you stop. The subject line is fine. It is the name in the second paragraph that will not come. You have met this man twice this year, you could describe his office, and the word sits behind something you cannot push. Your thumb rests on the trackpad. On the desk beside the keyboard, a coffee ring has dried into the shape of the cup you moved an hour ago. So you type a question into a search box, the way most people do at this hour, and end up reading about a mushroom sold for focus, next to a dosage someone posted with total confidence. Lion’s mane has not been tested in ADHD trials, and published guidance gives no dose for it. What follows is the state of the research rather than a recommendation: which of these supplements has been put to a controlled test in ADHD, in whom, with what result. We keep coming back to this because a blank cell and a failed cell look identical when you are scanning, and only one of them means a test was run.
What a useful study would have to measure
A trial that could settle this would fix a dose before anyone takes it, recruit people who already carry the diagnosis rather than volunteers who feel foggy, and keep both groups on it long enough for a real effect to have room to appear. It would name its outcome in advance: a validated attention scale, a working-memory task, or a count of the errors people actually make at work and school. Randomization, blinding and a report of dropouts are the boring parts, and they are the parts that decide whether a result means anything at all.
For lion’s mane, none of those elements is in place. Good human trials are scarce, and the material people circulate under this heading is not ADHD research.
It is the third evening in a row that you have stood at the kitchen counter reading the same short summary on your phone, because the sentence about attention did not stay. You put the container back in the cupboard without taking anything. At your desk the next morning you look up a name you already knew, and by Friday you have quietly stopped trusting recall for anything that matters: every appointment gets a second alarm, every name gets typed into your notes before you have finished the introduction. The reading pile grows and the decisions shrink, and you are no longer sure which part of that is the search and which part is the week.
An empty row is not a negative result
When a supplement has never been tested against ADHD, the table cell reads like a failure. It is not. It is an absence of measurement. Omega-3 sits on the other side of that line, because it has been tested repeatedly, and a 2023 review of 36 studies comparing polyunsaturated fatty acid supplements with placebo in children and adolescents found no evidence that ADHD symptoms are likely to improve. That is a finding, with a population attached. Lion’s mane has no such finding, in either direction.
The distinction matters when you are reading fast. A negative result constrains what anyone can claim from then on. An empty row constrains nothing, which is why it gets filled in by confident assertions and forum posts that never had to check themselves.
Ginkgo shows the other end of the scale. In the Ginkgo Evaluation of Memory study, funded by the National Center for Complementary and Integrative Health and the National Institute on Aging, more than 3,000 people age 75 or older with normal cognitive function or mild cognitive impairment were randomly assigned to ginkgo extract or placebo for a median of 6 years, with no difference in the rates at which dementia of any type developed. That trial says nothing about attention, and it also shows the size of machine required before anyone can speak plainly.
Tired of lion’s mane hype?Tested, or merely assumed?Watch the video on which of these supplements have real trials behind them in ADHD
Why the dose line stays blank
Published guidance gives no dose for lion’s mane in ADHD, because a dose only becomes meaningful once a trial has chosen one and reported what happened. People work backwards from that gap instead: a capsule strength is sold to them, halved out of caution, and the guess is then spoken about as if it were a protocol. Nothing in the record supports the guess, and nothing in the record rules it out either.
It is a point we make at length elsewhere: watch the full video if you want the slow version.
What bacopa and phosphatidylserine have actually got
These two names arrive in the same searches as lion’s mane, usually with a quantity attached and a sentence about attention written as though the matter were settled. What the evidence supports here is thinner than the sentences suggest. Good human trials on either one in ADHD are scarce, and this desk has no dose to pass along to an adult. Where a substance has been studied only in healthy volunteers doing memory tasks, that result does not travel to a person whose attention has been formally assessed.
Threads on forums, ranked lists and a quantity posted without a citation are a different kind of object from a controlled trial. Treat them as anecdotes that happened to be written down, which is still more than most of them are.
Two lines, since the point is short: the population was never the population you are. And a supplement that helps a score in a lab session has not thereby helped a workweek.
The evidence table in plain rows
Read across, not down. The first column is the question everyone asks, the last is the only column that carries weight.
Lion’s mane: tested in ADHD? No trial we can point to. Population: none established. Dose: no published guidance. Result: nothing measured.
Bacopa monnieri: tested in ADHD? Evidence too thin to summarize. Population: not established. Dose: no guidance we can give. Result: none we can report.
Phosphatidylserine: tested in ADHD? Same position. Population: not established. Dose: none published. Result: none reported.
Omega-3 fatty acids: tested in ADHD? Yes. Population: children and adolescents. Dose: types and amounts varied across studies, and no amount here is a recommendation. Result: the 2023 review of 36 studies found no evidence that symptoms are likely to improve, and called for more high-quality studies.
Behind a slip that keeps returning is a harder question. When one word vanishes mid-sentence, is the problem in getting the idea in, in holding it while you reach for something else, or in getting it back out again? Those three routes would need different evidence to tell apart, and this page does not settle which one is operating in you.
Talk to your prescriber
This page is not a substitute for an ADHD assessment or for any treatment you are already receiving. Do not stop, replace, or combine anything with stimulant medication without talking to the prescriber who manages it. Interactions are the ordinary way a supplement turns into a problem, and the reason a prescriber needs the whole list, including the items you consider harmless.
The blank cell and the failed cell
- A blank cell means the trial failed. Fact: it means no measurement was taken
- A negative result constrains what anyone can claim from then on
- An empty row constrains nothing, which is why assertions fill it
- Omega-3 sits on the tested side with a population attached
- Lion’s mane has no finding, in either direction
Children are outside the scope of anything written here about amounts; that conversation belongs with their doctor. A change in memory or attention that persists or worsens deserves a doctor’s time on its own, because the causes of memory trouble are several, never one. If a change comes on suddenly, with weakness, trouble speaking, or a severe headache, treat it as an emergency and call 911.
When the caveats have settled, the full session is the better use of an hour: watch the full video before you act on anything here.
Everything on Supplements & food →
▶ Watch the memory video
